MI-UPSTREAM-SECURITY
10.4.2024 16:07:32 CEST | Business Wire | Press release
Upstream Security, a leading provider of cybersecurity extended detection and response (XDR) for connected vehicles and IoT, today announced it received an investment from Cisco Investments. The proliferation of complex IoT devices in the Mobility, Automotive, and Transportation sectors introduces unprecedented operational efficiencies, data-driven services and solutions, and exceptional customer experience. However, advanced connectivity and software-defined components also open the door for large-scale cyber risks, threatening business availability and data integrity.
Upstream already protects millions of mobility connected vehicles and IoT devices worldwide, offering a cloud-based multi-layered approach to extended detection and response.
“We are thrilled to welcome Cisco Investments to our group of investors,” states Yoav Levy, Upstream Security Co-founder and CEO. “This investment provides a unique opportunity to deepen our impact on the IoT sector, and more specifically Mobility, Automotive and Transportation.”
This investment by Cisco Investments amplifies the need for purpose-built IoT cybersecurity solutions that will safeguard the mobility and IoT ecosystem across the entire development and production lifecycle.
“Together with our partners, Cisco is enabling automobile manufacturers across the globe to provide mission-critical, secure connectivity as cars transform into data centers on wheels," says Cisco Investments vice president, Aleem Rizvon. “With an expected 95% of new vehicles having embedded connectivity by the year 2030, we can also expect a rise in automotive cybersecurity threats. Investing in solutions, to ensure the right safeguards for secure connectivity and operation are in place, is critical to instill the trust needed for wide adoption of the technology, not just in the automotive segment, but more broadly for other IoT applications, as well.
Disrupting the IoT Cybersecurity Landscape
Upstream’s cloud-based IoT XDR platform analyzes, in real-time, the contextual state of physical IoT assets and their connected ecosystem, to holistically identify and mitigate cyber risks. The Platform is agentless, requiring no installation of software or hardware, enabling rapid deployment and comprehensive coverage of devices already in production.
The Platform ingests, parses, and normalizes vast amounts of connected vehicle data, IoT protocols, telematics, API transactions, and other data streams from tens of millions of devices, endpoints, and application consumers. This data enables the creation of unique digital twins—near real-time representations of devices and endpoints, facilitating holistic and effective detection. By monitoring devices, services, and overall asset behavior, the Platform detects both known and unknown anomalies based on proprietary ML-powered models.
Coupled with a purpose-built vehicle security operation center (vSOC), dedicated for monitoring and investigating connected vehicles and IoT cyber threats, Upstream provides a holistic suite of cybersecurity solutions and services to enable customers to proactively identify and remediate cyber threats. Utilizing Upstream’s Ocean AI, Generative AI-powered capabilities, accelerates the investigation remediation process.
About Upstream Security
Upstream provides a cloud-based data management platform purpose-built for mobility and IoT, delivering unparalleled cybersecurity extended detection and response (XDR) and data-driven applications. The Upstream Platform secures more than 25 million connected vehicles and IoT devices and is trusted by large vehicle manufacturers and IoT service providers.
Upstream recently published its 2024 Automotive Cybersecurity Report, providing a detailed analysis of the cyber landscape across the Automotive and Mobility ecosystem, emerging risks, and the evolving regulatory landscape.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410994590/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom